{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T01:37:56Z","timestamp":1767922676690,"version":"3.49.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.phrs.2016.08.013","type":"journal-article","created":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T06:43:14Z","timestamp":1470897794000},"page":"62-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"PA","title":["Novel, selective EPO receptor ligands lacking erythropoietic activity reduce infarct size in acute myocardial infarction in rats"],"prefix":"10.1016","volume":"113","author":[{"given":"Krisztina","family":"Kiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2532-6261","authenticated-orcid":false,"given":"Csaba","family":"Csonka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e1nos","family":"P\u00e1l\u00f3czi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judit","family":"Pipis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anik\u00f3","family":"G\u00f6rbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3870-3989","authenticated-orcid":false,"given":"Gabriella F.","family":"Kocsis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsolt","family":"Murlasits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rta","family":"S\u00e1rk\u00f6zy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1874-2718","authenticated-orcid":false,"given":"Gerg\u0151","family":"Sz\u0171cs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P.","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijun","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam\u00e1s","family":"Csont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehrdad","family":"Shamloo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn W.","family":"Woodburn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"Ferdinandy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1936-6232","authenticated-orcid":false,"given":"P\u00e9ter","family":"Bencsik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2016.08.013_bib0005","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejca.2006.10.014","article-title":"EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update","volume":"43","author":"Bokemeyer","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.phrs.2016.08.013_bib0010","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijcard.2013.12.011","article-title":"Erythropoietin and the heart: physiological effects and the therapeutic perspective","volume":"171","author":"Sanchis-Gomar","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.phrs.2016.08.013_bib0015","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1096\/fj.03-1289fje","article-title":"Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury","volume":"18","author":"Wright","year":"2004","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2016.08.013_bib0020","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jtcvs.2004.12.041","article-title":"Expression of the erythropoietin receptor in human heart","volume":"130","author":"Depping","year":"2005","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.phrs.2016.08.013_bib0025","doi-asserted-by":"crossref","first-page":"14907","DOI":"10.1073\/pnas.0406491101","article-title":"Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor","volume":"101","author":"Brines","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2016.08.013_bib0030","article-title":"Flipping the molecular switch for innate protection and repair of tissues: long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin","volume":"10","author":"Collino","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2016.08.013_bib0035","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/FJC.0b013e3181f4f05a","article-title":"Erythropoietin derivate improves left ventricular systolic performance and attenuates left ventricular remodeling in rats with myocardial infarct-induced heart failure","volume":"56","author":"Xu","year":"2010","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.phrs.2016.08.013_bib0040","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s10741-008-9084-z","article-title":"Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure","volume":"13","author":"Latini","year":"2008","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.phrs.2016.08.013_bib0045","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.jacc.2006.08.031","article-title":"Protective effects of erythropoietin in cardiac ischemia: from bench to bedside","volume":"48","author":"Lipsic","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2016.08.013_bib0050","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2147\/TCRM.S61551","article-title":"The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions","volume":"10","author":"Palazzuoli","year":"2014","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.phrs.2016.08.013_bib0055","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1126\/science.1098313","article-title":"Derivatives of erythropoietin that are tissue protective but not erythropoietic","volume":"305","author":"Leist","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.phrs.2016.08.013_bib0060","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.08.013_bib0065","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1001\/jama.2011.592","article-title":"Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial","volume":"305","author":"Najjar","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2016.08.013_bib0070","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1161\/CIRCINTERVENTIONS.109.904425","article-title":"Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial","volume":"3","author":"Ott","year":"2010","journal-title":"Circ. Cardiovasc. Interv."},{"key":"10.1016\/j.phrs.2016.08.013_bib0075","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.exphem.2006.05.012","article-title":"Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia","volume":"34","author":"Fan","year":"2006","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.phrs.2016.08.013_bib0080","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMc1400883","article-title":"Anaphylaxis and hypotension after administration of peginesatide","volume":"370","author":"Bennett","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.08.013_bib0085","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1073\/pnas.0409329102","article-title":"A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury","volume":"102","author":"Fiordaliso","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2016.08.013_bib0090","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1124\/jpet.105.094854","article-title":"Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties","volume":"316","author":"Moon","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2016.08.013_bib0095","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1161\/CIRCHEARTFAILURE.111.965061","article-title":"Asialoerythropoietin, a nonerythropoietic derivative of erythropoietin, displays broad anti-heart failure activity","volume":"5","author":"Takeyama","year":"2012","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.phrs.2016.08.013_bib0100","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.surg.2009.03.022","article-title":"Carbamylated erythropoietin protects the myocardium from acute ischemia\/reperfusion injury through a PI3K\/Akt-dependent mechanism","volume":"146","author":"Xu","year":"2009","journal-title":"Surgery"},{"key":"10.1016\/j.phrs.2016.08.013_bib0105","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2796.2008.02024.x","article-title":"Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response","volume":"264","author":"Brines","year":"2008","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.phrs.2016.08.013_bib0110","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1056\/NEJMoa011931","article-title":"Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin","volume":"346","author":"Casadevall","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.08.013_bib0115","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.exphem.2006.05.012","article-title":"Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia","volume":"34","author":"Fan","year":"2006","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.phrs.2016.08.013_bib0120","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2174\/1874467210902010056","article-title":"Molecular basis of cardioprotection by erythropoietin","volume":"2","author":"Burger","year":"2009","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.phrs.2016.08.013_bib0125","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00395-007-0672-1","article-title":"B-type natriuretic peptide at early reperfusion limits infarct size in the rat isolated heart","volume":"102","author":"Burley","year":"2007","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.phrs.2016.08.013_bib0130","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1373\/clinchem.2003.030510","article-title":"B-type natriuretic peptide (BNP) and N-terminal proBNP in patients with end-stage heart failure supported by a left ventricular assist device","volume":"50","author":"Kemperman","year":"2004","journal-title":"Clin. Chem."},{"key":"10.1016\/j.phrs.2016.08.013_bib0135","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.yjmcc.2010.01.013","article-title":"Biglycan protects cardiomyocytes against hypoxia\/reoxygenation injury: role of nitric oxide","volume":"48","author":"Csont","year":"2010","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.phrs.2016.08.013_bib0140","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00395-010-0097-0","article-title":"Role of cGMP-PKG signaling in the protection of neonatal rat cardiac myocytes subjected to simulated ischemia\/reoxygenation","volume":"105","author":"G\u00f6rbe","year":"2010","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.phrs.2016.08.013_bib0145","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.phrs.2013.12.007","article-title":"Moderate inhibition of myocardial matrix metalloproteinase-2 by ilomastat is cardioprotective","volume":"80","author":"Bencsik","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2016.08.013_bib0150","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.vascn.2010.02.014","article-title":"Measurement of myocardial infarct size in preclinical studies","volume":"61","author":"Csonka","year":"2010","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.phrs.2016.08.013_bib0155","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1073\/pnas.0630444100","article-title":"Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling","volume":"100","author":"Calvillo","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2016.08.013_bib0160","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/01.fjc.0000140209.04675.c3","article-title":"Timing of erythropoietin treatment for cardioprotection in ischemia\/reperfusion","volume":"44","author":"Lipsic","year":"2004","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.phrs.2016.08.013_bib0165","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00395-005-0537-4","article-title":"Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo","volume":"100","author":"Bullard","year":"2005","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.phrs.2016.08.013_bib0170","doi-asserted-by":"crossref","first-page":"H748","DOI":"10.1152\/ajpheart.00837.2005","article-title":"Erythropoietin affords additional cardioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3 beta","volume":"291","author":"Nishihara","year":"2006","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.phrs.2016.08.013_bib0175","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1203\/pdr.0b013e31805341dc","article-title":"Pharmacokinetics of high-dose recombinant erythropoietin in plasma and brain of neonatal rats","volume":"61","author":"Statler","year":"2007","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.phrs.2016.08.013_bib0180","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/FJC.0b013e318040cf81","article-title":"Darbepoetin alfa protects the rat heart against infarction: dose-response, phase of action, and mechanisms","volume":"49","author":"Baker","year":"2007","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.phrs.2016.08.013_bib0185","doi-asserted-by":"crossref","first-page":"H60","DOI":"10.1152\/ajpheart.00227.2007","article-title":"Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart","volume":"293","author":"Gao","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.phrs.2016.08.013_bib0190","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1016\/j.transproceed.2010.09.163","article-title":"B-type natriuretic peptide pretreatment attenuates heart ischemia-reperfusion injury in rats","volume":"42","author":"Ren","year":"2010","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.phrs.2016.08.013_bib0195","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1620\/tjem.219.107","article-title":"Pretreatment with B-type natriuretic peptide protects the heart from ischemia-reperfusion injury by inhibiting myocardial apoptosis","volume":"219","author":"Wu","year":"2009","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.phrs.2016.08.013_bib0200","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2143\/AC.63.3.1020316","article-title":"Postconditioning attenuates cardiocyte ultrastructure injury and apoptosis by blocking mitochondrial permeability transition in rats","volume":"63","author":"Fang","year":"2008","journal-title":"Acta Cardiol."},{"key":"10.1016\/j.phrs.2016.08.013_bib0205","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/bja\/aen022","article-title":"Hyperglycaemia blocks sevoflurane-induced postconditioning in the rat heart in vivo: cardioprotection can be restored by blocking the mitochondrial permeability transition pore","volume":"100","author":"Huhn","year":"2008","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.phrs.2016.08.013_bib0210","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1111\/j.1476-5381.2011.01691.x","article-title":"Cyclosporin variably and inconsistently reduces infarct size in experimental models of reperfused myocardial infarction: a systematic review and meta-analysis","volume":"165","author":"Lim","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2016.08.013_bib0215","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00395-013-0379-4","article-title":"Cyclosporine A at reperfusion fails to reduce infarct size in the in vivo rat heart","volume":"108","author":"De Paulis","year":"2013","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.phrs.2016.08.013_bib0220","doi-asserted-by":"crossref","first-page":"10925","DOI":"10.1073\/pnas.0805594105","article-title":"Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin","volume":"105","author":"Brines","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2016.08.013_bib0225","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2119\/molmed.2010.00235","article-title":"A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage","volume":"17","author":"Ahmet","year":"2011","journal-title":"Mol. Med."},{"key":"10.1016\/j.phrs.2016.08.013_bib0230","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.carrev.2015.01.008","article-title":"Administration of erythropoietin in patients with myocardial infarction: does it make sense? An updated and comprehensive meta-analysis and systematic review","volume":"16","author":"Ali-Hassan-Sayegh","year":"2015","journal-title":"Cardiovasc. Revasc. Med."},{"key":"10.1016\/j.phrs.2016.08.013_bib0235","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/tri.12174","article-title":"Erythropoietin-mediated protection in kidney transplantation: nonerythropoietic EPO derivatives improve function without increasing risk of cardiovascular events","volume":"27","author":"van Rijt","year":"2014","journal-title":"Transpl. Int."},{"key":"10.1016\/j.phrs.2016.08.013_bib0240","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2119\/molmed.2014.00215","article-title":"ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes","volume":"20","author":"Brines","year":"2015","journal-title":"Mol. Med."},{"key":"10.1016\/j.phrs.2016.08.013_bib0245","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/mds.25836","article-title":"Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxia","volume":"29","author":"Boesch","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.phrs.2016.08.013_bib0250","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1479-5876-11-9","article-title":"ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia\/reperfusion injury","volume":"11","author":"van Rijt","year":"2013","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.phrs.2016.08.013_bib0255","doi-asserted-by":"crossref","first-page":"334","DOI":"10.2119\/molmed.2013.00122","article-title":"ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density","volume":"19","author":"Dahan","year":"2013","journal-title":"Mol. Med."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661815301407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661815301407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T09:08:32Z","timestamp":1582535312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661815301407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":51,"alternative-id":["S1043661815301407"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2016.08.013","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel, selective EPO receptor ligands lacking erythropoietic activity reduce infarct size in acute myocardial infarction in rats","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2016.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}